Ipca surges 11% in tepid market, nears 52-week high on healthy Q1 results
Ipca Laboratories upgraded FY27 revenue growth guidance to 14-16 per cent from 12-13 per cent and raised consolidated EBITDA margin guidance to 23 per cent from 22 per cent.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.